Storia in 2 fonti

Latigo IPO raises nearly $350M for pain drug development

The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 g fa

Latigo IPO raises nearly $350M for pain drug development

The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

originale

endpoints.news1 g fa

BlossomHill, Latigo cap four-IPO week with combined $496M haul

BlossomHill ($BLSM) & Latigo ($LTGO) priced IPOs Thursday. BlossomHill targets AstraZeneca's Tagrisso; Latigo's LTG-001 rivals Vertex's Journavx in non-opioid pain.

Leggi questa versione → originale

Timeline cronologica

venerdì 7 agosto 2026·biopharmadive.com
Latigo IPO raises nearly $350M for pain drug development
The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in…
venerdì 7 agosto 2026·endpoints.news
BlossomHill, Latigo cap four-IPO week with combined $496M haul
BlossomHill ($BLSM) & Latigo ($LTGO) priced IPOs Thursday. BlossomHill targets AstraZeneca's Tagrisso; Latigo's LTG-001 rivals Vertex's Journavx in non-opioid pain.